Early Screening and Treatment of Heart Complication in Sickle Cell Disease
ConditionSickle Cell Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorInova Health Care Services
About this trial
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
Eligibility criteria
Qualifiers
At least 18 years of age
Diagnosis of sickle cell disease (any genotype)
Serum ferritin levels ≥ 400 ng/mL (up to 80 patients), or less than 400 ng/mL in those who have cardiac symptoms including shortness of breath and lower extremity edema (up to 20 patients)
Willingness to undergo regular imaging (echocardiograms, ECG, cardiac MRI)
Disqualifiers
Unable to schedule and required follow-up visits
Known heart failure
Unstable angina
Uncontrolled dysrhythmias
Trial design
Treatments tested in this trial
- Deferoxamine
- Deferasirox
- Deferiprone
- Echocardiography
- Electrocardiogram (ECG)
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov